Mizuho lifts target to USD 700 for Medpace stock

Published on 10/15/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medpace will report third-quarter results on October 21, 2026. Medpace stock costs EUR 561.60 on October 15, 2026 at 7:37 p.m. CEST.

Targets and reporting dates

Mizuho Securities raised its Medpace target from USD 665.00 to USD 700.00 on October 7, 2026.
Medpace will report third-quarter 2026 results on October 21, 2026.
Medpace stock costs EUR 561.60 at Lang & Schwarz on October 15, 2026 at 7:37 p.m. CEST.
Medpace trades at a P/E ratio of 36.92 and a market capitalization of USD 17.6 billion.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Mizuho Securities raised its Medpace target from USD 665.00 to USD 700.00 on October 7, 2026, according to The Globe and Mail. Against the USD 630.44 Nasdaq price at 1:42 p.m. EDT on October 15, 2026, the new target stands 11.03 percent higher. Medpace stock was trading at EUR 561.60 at Lang & Schwarz on October 15, 2026 at 7:37 p.m. CEST.

Target leaves room above Nasdaq price

The Mizuho target is the clearest dated valuation signal in the recent analyst coverage. Its increase from USD 665.00 to USD 700.00 represents a USD 35.00 step, while the target remains within the corridor set by recent broker views. The target is denominated in USD and is compared with the Nasdaq quotation in the same currency, not with the euro quotation.

Medpace's investor relations page lists 6,500 employees across 46 countries as of June 30, 2026. The company describes itself as a full-service clinical contract research organization serving biotechnology, pharmaceutical and medical-device clients through Phase I to Phase IV development services, according to Medpace.

Price position and valuation

The Nasdaq quotation was USD 630.44 on October 15, 2026 at 1:42 p.m. EDT, up 2.24 percent from USD 616.63. Medpace's 52-week range was USD 373.00 to USD 677.90, placing the quotation 6.99 percent below the high. Trading volume reached 130,370 shares against an average of 269,153 shares.

Market capitalization stood at USD 17.6 billion as of October 15, 2026, while the P/E ratio was 36.92. The company had no reported trailing dividend yield in the same market snapshot. Medpace is scheduled to report third-quarter 2026 results after the Nasdaq close on October 21, 2026, with its conference call set for October 22, according to Business Wire.

Comparison with peers

Medpace: plus 2.24 percent, P/E 36.92, market capitalization USD 17.6 billion

IQVIA Holdings (NYSE, USD): plus 3.03 percent, P/E 33.51, market capitalization USD 44.4 billion

ICON (Nasdaq, USD): plus 3.32 percent, P/E 41.02, market capitalization USD 13.5 billion

Next reporting date sets the calendar

The October 21 results date is the next scheduled company event. For investors, the combination of a USD 700.00 analyst target, a USD 630.44 Nasdaq quotation and a 6.99 percent distance from the 52-week high defines the current market setup.

The further course of trading is shown by the continuously updated real-time quote of Medpace Holdings stock.